Abeona Therapeutics Inc - Asset Resilience Ratio
Abeona Therapeutics Inc (ABEO) has an Asset Resilience Ratio of 51.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Abeona Therapeutics Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Abeona Therapeutics Inc's Asset Resilience Ratio has changed over time. See how leveraged is Abeona Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Abeona Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ABEO market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $112.97 Million | 51.45% |
| Total Liquid Assets | $112.97 Million | 51.45% |
Asset Resilience Insights
- Very High Liquidity: Abeona Therapeutics Inc maintains exceptional liquid asset reserves at 51.45% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Abeona Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Abeona Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Abeona Therapeutics Inc (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Abeona Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 51.45% | $112.97 Million | $219.57 Million | -16.82pp |
| 2024-12-31 | 68.27% | $74.36 Million | $108.93 Million | +9.28pp |
| 2023-12-31 | 58.99% | $37.75 Million | $64.00 Million | -0.08pp |
| 2022-12-31 | 59.07% | $37.93 Million | $64.21 Million | +43.89pp |
| 2021-12-31 | 15.19% | $12.09 Million | $79.59 Million | -39.34pp |
| 2020-12-31 | 54.52% | $82.44 Million | $151.20 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $223.38 Million | -- |
| 2018-12-31 | 37.97% | $66.22 Million | $174.40 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $178.77 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $111.06 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $80.06 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $16.58 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $1.73 Million | -- |
| 2011-12-31 | 8.72% | $330.00K | $3.79 Million | -65.19pp |
| 2007-12-31 | 73.91% | $6.76 Million | $9.15 Million | +24.19pp |
| 2006-12-31 | 49.72% | $3.19 Million | $6.43 Million | +47.99pp |
| 2005-12-31 | 1.73% | $125.00K | $7.21 Million | -2.65pp |
| 2004-12-31 | 4.38% | $486.00K | $11.09 Million | -11.37pp |
| 2003-12-31 | 15.75% | $1.86 Million | $11.81 Million | -27.01pp |
| 2002-12-31 | 42.76% | $8.33 Million | $19.49 Million | -7.07pp |
| 2001-12-31 | 49.83% | $12.70 Million | $25.49 Million | -7.15pp |
| 2000-12-31 | 56.98% | $17.39 Million | $30.53 Million | -- |
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more